Navigation Links
NYU College of Nursing's Dr. Anastasi awarded $2.5 million from NIH to study IBS symptom management
Date:8/6/2012

New York University College of Nursing's (NYUCN) Joyce K. Anastasi, PhD, DrNP, FAAN, LAc., the Independence Foundation Endowed Professor and Founding Director of the Division of Special Studies in Symptom Management at NYUCN has been awarded a $2.5 million four-year National Institutes of Health (NIH) grant for the study of "Symptom management for irritable bowel syndrome (IBS) constipation".

The primary aim of the study is to investigate the efficacy of Acupuncture/Moxibustion (Acu/Moxa) in reducing abdominal pain/discomfort and IBS secondary supporting symptoms such as intestinal gas, bloating, and stool consistency. The randomized, blinded, sham/placebo controlled study, with 183 adults diagnosed with IBS-Constipation, will follow the accepted standards of rigorous clinical trials.

"Acu/Moxa , used in traditional Chinese medicine, has been employed successfully to manage various GI disorders including IBS," said Dr. Anastasi. "However, few acupuncture studies have had the necessary rigor to evaluate this therapy," she said.

IBS is the most commonly identified functional bowel disorder afflicting 15% to 20% of North Americans. IBS is defined as abdominal pain/discomfort in the mid or lower gastrointestinal (GI) tract, associated with defecation or a change in bowel patterns with features of disordered defecation.

The chronic symptoms of IBS have been linked with decreased quality of life, decreased work productivity, and increased health care utilization. Few current therapies such as dietary modification, supplements, psychotherapy and pharmacologic agents are proven effective, either singly or in combination. Most [studies] said Dr. Anastasi, "have been limited by size, design and duration of follow-up."

Dr. Anastasi is one of the country's leading clinical scientists in the area of symptom management. Over the past three years, Dr. Anastasi has been awarded three NIH R01s, all of which have contributed to developing rigorously tested, randomized clinical trials using non-invasive interventions to manage chronic and often debilitating symptoms. Her studies provide the foundation to develop clinically meaningful interventions to guide researchers, clinicians and patients to understand the therapeutic benefits of methods such as traditional Chinese medicine.

Dr. Anastasi served on the Advisory Board for the Institute of Medicine's (IOM) report on The Use of Complementary and Alternative Medicine by the American Public. Dr. Anastasi, a nurse scientist, clinical trialist is also an acupuncturist, Diplomate from the NCCAOM. Dr. Anastasi authored and developed the Herbs, Nutraceuticals and Dietary Supplements graduate program funded by the Health Resources and Services Administration (HRSA). She has published extensively in the area of symptom management using non-invasive interventions and has received numerous awards for her contributions and expertise in acupuncture and symptom management research.


'/>"/>

Contact: Christopher James
christopher.james@nyu.edu
212-998-6876
New York University
Source:Eurekalert

Related biology news :

1. UC Berkeley survey shows college campuses can make good bird havens
2. College students work to sterilize air, kill pathogens on buses
3. Study by Haverford College professor reveals unprecedented impact of Deepwater Horizon on deep ocean
4. American College of Rheumatology releases first classification criteria for polymyalagia rheumatica
5. OU research group awarded $9.7 million NIH CoBRE grant in structural biology
6. UC Riverside graduate student awarded Guru Gobind Singh Fellowship
7. $5 million grant awarded to UC Riverside to study immortality
8. UTMB scientists awarded NIH grant for lab-grown lung tissue project
9. Danforth Center awarded $12 million to study drought
10. VESAG mHealth watch awarded CE, ROHS and SAR certifications
11. NOAA scholarship awarded to Jan Vicente to study the impact of ocean acidification on marine sponges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
(Date:3/29/2016)... BOCA RATON, Florida , March 29, 2016 /PRNewswire/ ... ("LegacyXChange" or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect ... Synthetic DNA in ink used in a variety of ... preventing theft. Buyers of originally created collectibles from athletes ... authenticity through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):
(Date:4/26/2016)... ... April 27, 2016 , ... ... Rothgerber Christie LLP as an associate in the firm’s Intellectual Property practice group. ... mechanical and electromechanical patent applications. He has an electrical engineering and computer engineering ...
(Date:4/26/2016)... ... ... The European Patent Office (EPO) today announced that U.S. ... European Inventor Award 2016 in the category "Non-European countries." The winners of the 11th ... Lisbon on June 9th. , The human capacity to walk with fluidity is the ...
(Date:4/26/2016)... ... April 26, 2016 , ... Mr. Palmer created the RPO ... the first multi-million dollar, multi-year managed services contract in the U.S. intelligence community with ... our leadership team,” said John Younger, founder of Accolo. “We are growing and ...
(Date:4/26/2016)... , ... April 26, 2016 , ... BioFactura, Inc ... Series A round of financing. Healthy investor interest drove significant oversubscription of the ... generic biologics, known as biosimilars, to the advanced preclinical stages. , Chief Executive Officer ...
Breaking Biology Technology: